↑ 疾患リストへ ← 戻る

 227. オスラー病 [臨床試験数:38,薬物数:44(DrugBank:18),標的遺伝子数:12,標的パスウェイ数:24] 

Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04113187December 201914 October 2019Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia PatientsStudy of the Efficacy of Propranolol for the Management of Epistaxis in Hereditary Hemorrhagic Telangiectasia PatientsHereditary Hemorrhagic Telangiectasia;Osler Weber Rendu DiseaseDrug: Propranolol treatment;Drug: PlaceboUniversity Hospital, BordeauxAMRO-HHT-France - Association Maladie de Rendu-OslerNot recruiting18 YearsN/AAll38Phase 3France
2NCT04139018October 20, 20194 November 2019Timolol Gel for Epistaxis in Hereditary Hemorrhagic TelangiectasiaEfficacy of a Timolol Gel in the Care for Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia: A Double-Blinded, Randomized Controlled TrialHereditary Hemorrhagic TelangiectasiaDrug: Timolol Gel;Drug: Placebo GelWashington University School of MedicineInstitute of Clinical and Translational Sciences (ICTS)Recruiting20 YearsN/AAll30Phase 2United States
3NCT03910244October 201926 August 2019Pomalidomide for the Treatment of Bleeding in HHTPomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic TelangiectasiaTelangiectasia, Hereditary HemorrhagicDrug: Pomalidomide Oral Product;Drug: Placebo oral capsuleThe Cleveland ClinicRTI InternationalNot recruiting18 Years99 YearsAll159Phase 2
4NCT03850730September 20194 March 2019Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic TelangiectasiaAn Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia;EpistaxisDrug: PazopanibCure HHTUniversity of North CarolinaNot recruiting18 Years75 YearsAll30Phase 1/Phase 2
5NCT03850964September 20194 March 2019Pazopanib Effects on Bleeding in Hereditary Hemorrhagic TelangiectasiaRandomized Double Blind Study to Evaluate the Effect of Low Dose Pazopanib on Bleeding Due to Hereditary Hemorrhagic TelangiectasiaHereditary Hemorrhagic Telangiectasia;Epistaxis Nosebleed;AnemiaDrug: Pazopanib;Drug: Placebo oral capsuleCure HHTNot recruiting18 Years75 YearsAll45Phase 2/Phase 3
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03397004September 12, 201821 January 2019Doxycycline for Hereditary Hemorrhagic TelangiectasiaDoxycycline Crossover Trial for Hereditary Hemorrhagic TelangiectasiaHereditary Hemorrhagic Telangiectasia (HHT)Drug: Doxycycline Hyclate;Drug: PlaceboSt. Michael's Hospital, TorontoBarrow Neurological Institute;Duke University;Feinstein Institute for Medical Research;University of Pittsburgh;Sunnybrook Health Sciences CentreRecruiting18 YearsN/AAll30Phase 2Canada
7NCT03981562July 16, 201824 June 2019Vitamin D and Hereditary Haemorrhagic TelangiectasiaVitamin D Supplementation and Reduction of Severity and Frequency of Epistaxis in Hereditary Haemorrhagic TelangiectasiaHereditary Haemorrhagic TelangiectasiaDrug: Vit D;Drug: Placebo Oral TabletSt. Paul's Hospital, CanadaRecruiting19 YearsN/AAll60Phase 2Canada
8NCT03572556June 28, 201810 December 2018Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic TelangiectasiaBiological: Blood samples;Other: Epistaxis chartsCentre Hospitalier Universitaire DijonRecruiting18 YearsN/AAll50Phase 1France
9EUCTR2017-003272-31-NL18/05/20185 June 2018Itraconazole as treatment for severe nose bleeding in patients with hereditary hemorrhagic telangiectasiaEfficacy and safety of oral itraconazole in the reduction of epistaxis severity in hereditary hemorrhagic telangiectasia - Itraconazole for epistaxis in HHT patientsSevere epistaxis in patients with Hereditary Hemorrhagic Telangiectasia also known as Rendu-Osler-Weber disease
MedDRA version: 20.0 Level: LLT Classification code 10031132 Term: Osler-Weber-Rendu disease System Organ Class: 100000004850
MedDRA version: 20.0 Level: LLT Classification code 10038554 Term: Rendu-Osler-Weber syndrome System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Sporanox
Product Name: Itraconazole
Pharmaceutical Form: Capsule
St. Antonius ZiekenhuisAuthorisedFemale: yes
Male: yes
25Phase 2Netherlands
10NCT02963129June 201721 November 2016Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHTTreatment of Nasal Staphylococcus Aureus Colonization in Patients With Hereditary Hemorrhagic Telangiectasia With Recurrent Epistaxis.Hereditary Hemorrhagic Telangiectasia;EpistaxisDrug: Mupirocin;Other: PlaceboHospital Italiano de Buenos AiresNot recruiting18 YearsN/ABoth40Phase 3Argentina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2016-003982-24-ES16/03/201728 February 2019Study to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of hereditary hemorrhagic telangiectasia, during 4 weeksA phase IV-II, single-center, open, single arm treatment, low level of intervention, to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of hereditary hemorrhagic telangiectasia, during 4 weeksHereditary hemorrhagic telangiectasia
MedDRA version: 19.0 Level: LLT Classification code 10020023 Term: HHT System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Dicynone
CAS Number: 2624­44­4
Current Sponsor code: Etamsylate
Other descriptive name: ETAMSYLATE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 125-
Asociación HHT EspañaNot Recruiting Female: yes
Male: yes
12Phase 2;Phase 4Spain
12NCT02874326October 201611 June 2018Octreotide in Patients With GI Bleeding Due to Rendu-Osler-WeberAn Uncontrolled, Pilot-study Assessing the Efficacy of Octreotide Long-acting Release to Decrease Transfusion Requirements and Endoscopy Frequency in Patients With Rendu-Osler-Weber and Gastrointestinal BleedingHereditary Hemorrhagic Telangiectasia;Gastrointestinal Hemorrhage;AnemiaDrug: Octreotide LARRadboud UniversitySt. Antonius HospitalNot recruiting18 YearsN/AAll15Phase 2Netherlands
13EUCTR2016-001340-19-NL21/07/20168 August 2016The effectiveness of the drug octreotide LAR to anemia in patients with gastrointestinal bleeding due to Rendu-Osler-Weber disease.An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleeding - ROWPatients with Rendu-Osler-Weber disease (which is also called: Hereditary hemorrhagic telangiectasia);Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Trade Name: Sandostatin LAR 20 mg
Product Name: Sandostatin LAR
Product Code: RVG 18236
Pharmaceutical Form: Powder and solution for solution for injection
Radboud University Medical CenterAuthorisedFemale: yes
Male: yes
Phase 2Netherlands
14NCT02638012December 201524 June 2019Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT);EpistaxisDrug: Floseal;Other: PackingSt. Michael's Hospital, TorontoThe Ottawa HospitalRecruiting18 YearsN/AAll10N/ACanada
15NCT02484716June 201512 February 2018Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - Randomized Trial Versus PlaceboHemorrhagic Hereditary Telangiectasia (HHT)Drug: Timolol nasal spray;Drug: Placebo nasal sprayHospices Civils de LyonNot recruiting18 YearsN/AAll58Phase 2France
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT02287558January 27, 201520 August 2018Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I StudyA Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory AngiodysplasiaHereditary Hemorrhagic Telangiectasia;Idiopathic Vascular EctasiaDrug: PomalidomideThe Cleveland ClinicRecruiting18 YearsN/AAll9Phase 1United States
17NCT02157987December 201419 February 2015Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective DoseTreatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective DoseTelangiectasia, Hereditary HemorrhagicDrug: bevacuzimab sprayUniversity Hospital, CaenRecruiting18 Years70 YearsBoth30Phase 1/Phase 2France
18NCT02389959August 201416 December 2017Intranasal Bevacizumab for HHT-Related EpistaxisIntranasal Bevacizumab for HHT-Related EpistaxisHHT;Hereditary Hemorrhagic Telangiectasia;Epistaxis;Nose Bleeds;Nasal BleedingDrug: Bevacizumab;Drug: Placebo (Saline)Stanford UniversityRecruiting18 YearsN/AAll40Phase 4United States
19NCT02106520April 20147 December 2015Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia;EpistaxisDrug: Bevacizumab;Drug: placeboHospices Civils de LyonNot recruiting18 YearsN/ABoth80Phase 2/Phase 3France
20EUCTR2013-004204-19-FR26/02/20147 December 2015Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-OslerEfficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler - ALEGORIRendu-Osler disease
MedDRA version: 18.0 Level: LLT Classification code 10031132 Term: Osler-Weber-Rendu disease System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Avastin
Product Name: Avastin
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: BEVACIZUMAB
CAS Number: 216974-75-3
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Nasal use
Hospices Civils de LyonNot RecruitingFemale: yes
Male: yes
France
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT01908543July 201322 October 2019Iron Deficiency and Hereditary Haemorrhagic TelangiectasiaIron Deficiency and Hereditary Haemorrhagic TelangiectasiaHereditary Haemorrhagic TelangiectasiaDrug: Ferrous sulphate 200mg oral tabletImperial College LondonNot recruiting18 Years80 YearsAll3N/AUnited Kingdom
22NCT01752049May 201330 September 2019Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of ConceptTopical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of ConceptHereditary Hemorrhagic TelangiectasiaDrug: Topical timolol maleate;Drug: placebo saline dropsSt. Michael's Hospital, TorontoUniversity of California, San Francisco;The Hospital for Sick Children;University of Toronto;Sunnybrook Health Sciences Centre;Ryerson University;National Institute of Neurological Disorders and Stroke (NINDS)Not recruiting18 YearsN/AAll5N/ACanada
23NCT01485224November 201116 December 2017Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic TelangiectasiaEfficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia;EpistaxisDrug: ThalidomideIRCCS Policlinico S. MatteoNot recruiting18 YearsN/AAll31Phase 2Italy
24NCT01507480October 201119 February 2015The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic TelangiectasiaThe ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia.Hemorrhagic Hereditary TelangiectasiaDrug: BevacizumabHospices Civils de LyonNot recruiting18 YearsN/ABoth42Phase 1France
25NCT01408030August 201122 October 2018North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)North American Study of Epistaxis in HHT (NOSE)Telangiectasia, Hereditary Hemorrhagic;EpistaxisDrug: Sterile saline;Drug: Bevacizumab;Drug: Estriol;Drug: Tranexamic AcidJames GossageHHT Foundation InternationalNot recruiting18 YearsN/AAll123Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT01406639July 201119 February 2015Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Ranibizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT);NosebleedsDrug: RanibizumabUniversity of California, San DiegoGenentech, Inc.Not recruiting18 YearsN/ABoth0Phase 1United States
27NCT01408732February 201111 November 2019Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic TelangiectasiaOffice-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic TelangiectasiaEpistaxis;Hereditary Hemorrhagic TelangiectasiaDrug: Sclerotherapy;Other: Standard TreatmentUniversity of MinnesotaAmerican Rhinologic SocietyNot recruiting18 YearsN/AAll18Phase 1/Phase 2United States
28EUCTR2009-018049-19-AT13/12/201012 May 2014A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHTA randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHTepistaxisTrade Name: AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung
Pharmaceutical Form: Solution for injection
INN or Proposed INN: BEVACIZUMAB
CAS Number: 216974-75-3
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: -10
Trade Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung
Product Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung
Pharmaceutical Form: Solution for injection
CAS Number: 7647-14-5
Other descriptive name: SODIUM CHLORIDE
Concentration unit: ml millilitre(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intranasal use (Noncurrent)
Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und OhrenkrankheitenNot RecruitingFemale: yes
Male: yes
30Austria
29NCT01402531July 201019 February 2015Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT)Drug: Submucosal BevacizumabUniversity of California, San DiegoRecruiting18 YearsN/ABoth30Phase 2United States
30NCT01397695June 200919 February 2015Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT)Drug: BevacizumabUniversity of California, San DiegoRecruiting18 YearsN/ABoth50Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31EUCTR2008-006755-44-FR15/01/200919 March 2012METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFOREMETAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFOREMaladie de Rendu-Osler
MedDRA version: 9.1 Level: LLT Classification code 10031132 Term: Osler-Weber-Rendu disease
Trade Name: AVASTIN
Product Name: AVASTIN
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: BEVACIZUMAB
Other descriptive name: SUB16402MIG
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 25-
HOSPICES CIVILS DE LYONAuthorisedFemale: yes
Male: yes
Phase 2France
32EUCTR2010-020545-26-IT09/12/200819 March 2012BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - NDBEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - NDHEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
MedDRA version: 9.1 Level: SOC Classification code 10005329
Trade Name: AVASTIN
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: Bevacizumab
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 25-
Trade Name: AVASTIN
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: Bevacizumab
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 25-
Trade Name: AVASTIN
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: Bevacizumab
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 25-
AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALEAuthorisedFemale: yes
Male: yes
Italy
33NCT00588146January 200719 October 2017Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic TelangiectasiaPhase 2 Study of PEG-Intron in Hereditary Hemorrhagic TelangiectasiaAnemia;Liver Disease;HypoxemiaDrug: Pegylated Interferon Alpha2b;Other: Standard careMayo ClinicAugusta University;St. Michael's Hospital, Toronto;Schering-PloughNot recruiting18 Years70 YearsAll10Phase 2United States
34NCT00389935October 200619 February 2015Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal BleedingThalidomide Reduces Arteriovenous Malformation Related Gastrointestinal BleedingArteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;MelenaDrug: ThalidomideNorthport Veterans Affairs Medical CenterGeorgia Regents University;University of Massachusetts, WorcesterNot recruiting18 YearsN/ABoth14Phase 2United States
35NCT00375622February 200519 February 2015Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical TrialHereditary Hemorrhagic TelangiectasiaDrug: TamoxifenRabin Medical CenterNot recruiting18 YearsN/ABoth60Phase 2Israel
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT01031992March 200219 February 2015Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic TelangiectasiaHereditary Hemorrhagic TelangiectasiaDrug: Tranexamic acid first, than placebo;Drug: First placebo, than Tranexamic acid.University Hospital, SaarlandPharmacia GmbH, Erlangen, Germany;Baxter Healthcare CorporationNot recruiting18 YearsN/ABoth23Phase 3Germany
37NCT00004654January 199619 February 2015Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic TelangiectasiaHereditary Hemorrhagic TelangiectasiaDrug: soy protein isolateNational Center for Research Resources (NCRR)Yale UniversityNot recruiting15 YearsN/ABoth60Phase 3
38NCT00004327January 199519 February 2015Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile EctasiaHereditary Hemorrhagic Telangiectasia;EctasiaDrug: octreotideNational Center for Research Resources (NCRR)Yale UniversityNot recruitingN/AN/ABoth8Phase 2

先頭へ